{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.2","upperLimit":"95.8","value":"87.5"},{"groupId":"OG001","lowerLimit":"35.3","upperLimit":"57.7","value":"46.3"},{"groupId":"OG002","lowerLimit":"12.5","upperLimit":"32.9","value":"21.4"},{"groupId":"OG003","lowerLimit":"21.1","upperLimit":"78.9","value":"50.0"},{"groupId":"OG004","lowerLimit":"43.5","upperLimit":"65.7","value":"54.8"},{"groupId":"OG005","lowerLimit":"5.8","upperLimit":"22.1","value":"12.3"},{"groupId":"OG006","lowerLimit":"7.3","upperLimit":"21.0","value":"13.1"},{"groupId":"OG007","lowerLimit":"13.2","upperLimit":"52.9","value":"30.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"84"},{"groupId":"OG005","value":"73"},{"groupId":"OG006","value":"107"},{"groupId":"OG007","value":"23"}],"units":"Participants"}],"description":"The endpoint of ORR defined as the percentage of patients with a best response of CR or PR using RECIST v 1.1 or a response per Gynecologic Cancer InterGroup cancer antigen 125 (GCIG CA-125) criteria. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. A response to CA-125 has occurred if there is at least a 50% decrease from baseline: 1. in a sample collected after initiation of study treatment AND 2. that is confirmed in a subsequent sample collected ≥21 days after the prior sample. The absolute value of this confirmatory sample must be ≤110% of the prior sample. The date when the first sample with a 50% decrease from baseline is observed is the date of the CA-125 response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG000","title":"Part 1: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG001","title":"Part 1: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG002","title":"Part 1: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG003","title":"Part 1: Non-tBRCA LOH Unknown"},{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG004","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG005","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG006","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG007","title":"Part 2: Non-tBRCA LOH Unknown"}],"paramType":"NUMBER","populationDescription":"Safety population by HRD subgroups: Consist of all Part 1 and Part 2 patients who received at least one dose of rucaparib.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.","title":"Objective Response Rate (ORR) by RECIST v1.1 and GCIG CA-125 Criteria","type":"SECONDARY","unitOfMeasure":"percentage of patients"}